Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab in Routine Clinical Practice in the United Arab Emirates: ILLUMINATE-HS, a Prospective Patient Surve
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs Secukinumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms ILLUMINATE-HS
- Sponsors Novartis Pharmaceuticals
- 24 Jan 2025 New trial record